Murielle M. Véniant

Amgen (United States) — United States

Medicine · Health Sciences

50h-index8.8kcitations117works59.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(20), Pancreatic function and diabetes(17), Fibroblast Growth Factor Research(17), Metabolism, Diabetes, and Cancer(16), Hormonal Regulation and Hypertension(16)

Publications117 total

GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale
Diabetes·2025· 4 citedOpen Access
GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice
Nature Metabolism·2025· 14 citedOpen Access
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings
Nature Metabolism·2024· 160 citedOpen Access
A transcriptomic and proteomic atlas of obesity and type 2 diabetes in cynomolgus monkeys
Cell Reports·2023· 20 citedOpen Access
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and MultipleAscending Dose Study of AMG 133 in Subjects with Obesity
Metabolism·2023· 6 cited
<i>GIPR</i> gene expression in testis is mouse specific and can impact male mouse fertility
Andrology·2022· 5 cited
A Transcriptomic and Proteomic Atlas of Obesity and Type 2 Diabetes in Cynomolgus Monkeys
SSRN Electronic Journal·2022· 1 citedOpen Access
A Transcriptomic and Proteomic Atlas of Obesity and Type 2 Diabetes in Cynomolgus Monkeys
2021Open Access
GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys
Cell Reports Medicine·2021· 80 citedOpen Access
Growth differentiation factor 15 as a potential therapeutic for treating obesity
Molecular Metabolism·2020· 49 citedOpen Access
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
Nature Communications·2020· 129 citedOpen Access
Hsa-miRNA-23a-3p promotes atherogenesis in a novel mouse model of atherosclerosis
Journal of Lipid Research·2020· 23 citedOpen Access
The evolving systemic biomarker milieu in obese ZSF1 rat model of human cardiometabolic syndrome: Characterization of the model and cardioprotective effect of GDF15
PLoS ONE·2020· 27 citedOpen Access
Cardiovascular response to small-molecule APJ activation
JCI Insight·2020· 43 citedOpen Access
The evolving systemic biomarker milieu in obese ZSF1 rat model of human cardiometabolic syndrome: Characterization of the model and cardioprotective effect of GDF15
2020· 6 citedOpen Access
Molecular mechanism of an antagonistic antibody against glucose-dependent insulinotropic polypeptide receptor
mAbs·2020· 8 citedOpen Access
FGF21 acts as a negative regulator of bile acid synthesis
Endocrine Abstracts·2019· 1 cited
Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies For The Treatment Of Obesity, Do Agonists = Antagonists?
Endocrine Reviews·2019· 4 cited
Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?
Endocrine Reviews·2019· 88 citedOpen Access
CCDC 1948985: Experimental Crystal Structure Determination
The Cambridge Structural Database·2019Open Access
page 1 of 6Next →

Frequent Co-authors

Stephen G. Young(14), Renée Komorowski(14), Shanaka Stanislaus(12), Jing Xu(11), Richard Lindberg(11), Clarence Hale(10), Todd Hager(10), David J. Lloyd(8), Randy Hecht(8), Glenn Sivits(7), Yang Li(7), Minghan Wang(7), Michelle Chen(6), Yuesheng Li(6), Constance Zlot(5), Narumol Chinookoswong(5), Shu-Chen Lu(5), Junming Yie(5), Larissa Atangan(5), Jennifer Weiszmann(5)